1. Isidori A. et al. Iron toxicity - Its effect on the bone marrow. // Blood Rev. England, 2018. Vol. 32, № 6. P. 473–479.
2. Marsh J.C.W., Kulasekararaj A.G. Management of the refractory aplastic anemia patient: what are the options? // Blood. 2013. Vol. 122, № 22. P. 3561–3567.
3. Frickhofen N. et al. Antithymocyte globulin with or without cyclosporin A: 11-Year follow-up of a randomized trial comparing treatments of aplastic anemia // Blood. 2003. Vol. 101, № 4. P. 1236–1242.
4. Kulasekararaj A.G. et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome // Blood. 2014. Vol. 124, № 17. P. 2698–2704.
5. Afable M.G., Tiu R. V, Maciejewski J.P. Clonal Evolution in Aplastic Anemia // Hematology. 2011. № 1. P. 90–95.
6. Pu J.J. et al. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia // Eur. J. Haematol. 2011. Vol. 87, № 1. P. 37–45.
7. Socié G. et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors // Lancet. 1996. Vol. 348, № 9027. P. 573–577.
8. Kulagin A. et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: Results of two-centre prospective study // Br. J. Haematol. 2014. Vol. 164, № 4. P. 546–554.
9. Li Y. et al. Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: A single-center experience // Ann. Hematol. 2011. Vol. 90, № 5. P. 529–537.
10. Кулагин А.Д., Лисуков И.А., Птушкин В.В., Шилова Е.Р., Цветаева Н.В. М.Е.А. Национальные рекомендации по диагностике и лечениюпроксизмальной ночной гемоглобинурии // Онкогематология. 2014. Vol. 2. P. 20–28.
11. Kaufman D.W. et al. Relative incidence of agranulocytosis and aplastic anemia // Am. J. Hematol. 2006.
12. Михайлова Е.А., Савченко В.Г. Протокол программного лечения больных апластической анемией: комбинированная иммуносупрессивная терапия // Программное лечение заболеваний системы крови / ed. В.Г.Савченко. Москва: Практика, 2012. P. 135–150.
13. Killick S.B. et al. Guidelines for the diagnosis and management of adult aplastic anaemia. // Br. J. Haematol. England, 2016. Vol. 172, № 2. P. 187–207.
14. Soulier J. Fanconi anemia. // Hematology Am. Soc. Hematol. Educ. Program. 2011. Vol. 2011. P. 492–497.
15. Camitta B.M. What is the definition of cure for aplastic anemia? // Acta Haematologica. 2000. Vol. 103, № 1. P. 16–18.
16. Dokal I. Dyskeratosis congenita. // Hematology. 2011. Vol. 2011. P. 480–486.
17. Marsh J.C.W. et al. Guidelines for the diagnosis and management of aplastic anaemia // Br. J. Haematol. 2009. Vol. 147, № 1. P. 43–70.
18. Peslak S.A., Olson T., Babushok D. V. Diagnosis and Treatment of Aplastic Anemia // Current Treatment Options in Oncology. Springer New York LLC, 2017. Vol. 18, № 12.
19. Пантелеев М.А. et al. Практическая коагулология. 2010. 192 p.
20. Hayward C.P.M. How I investigate for bleeding disorders // International Journal of Laboratory Hematology. Blackwell Publishing Ltd, 2018. Vol. 40. P. 6–14.
21. Nielsen P. et al. Iron Stores in Patients with Myelodysplasia and Aplastic Anemia. // Blood. 2006. Vol. 108, № 11. P. 3726–3726.
22. DeZern A.E., Churpek J.E. Approach to the diagnosis of aplastic anemia // Blood Adv. American Society of Hematology, 2021. Vol. 5, № 12. P. 2660–2671.
23. Kelsey P. et al. Guidelines for the use of platelet transfusions // Br. J. Haematol. 2003. Vol. 122, № 1. P. 10–23.
24. Maciejewski J.P., Mufti G.J. Whole genome scanning as a cytogenetic tool in hematologic malignancies // Blood. 2008. Vol. 112, № 4. P. 965–974.
25. Maciejewski J.P. et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia // Blood. 2002. Vol. 99, № 9. P. 3129–3135.
26. Gupta V. et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults // Br. J. Haematol. 2006. Vol. 134, № 1. P. 95–99.
27. Miano M., Dufour C. The diagnosis and treatment of aplastic anemia: a review // Int. J. Hematol. 2015. Vol. 101, № 6. P. 527–535.
28. Dumitriu B. et al. Red cells, iron, and erythropoiesis: Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia // Blood. 2015. Vol. 125, № 4. P. 706–709.
29. Jerez A. et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients // Blood. 2013. Vol. 122, № 14. P. 2453–2459.
30. Du Y. et al. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload. // Acta Haematol. Switzerland, 2017. Vol. 138, № 2. P. 119–128.
31. Borowitz M.J. et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry // Cytom. Part B - Clin. Cytom. Wiley-Liss Inc., 2010. Vol. 78, № 4. P. 211–230.
32. Ogawa S. Clonal hematopoiesis in acquired aplastic anemia // Blood. 2016. Vol. 128, № 3. P. 337–347.
33. Parker C.J. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. // Hematology. United States, 2016. Vol. 2016, № 1. P. 208–216.
34. Brown K.E. et al. Hepatitis-associated aplastic anemia // N. Engl. J. Med. 1997. Vol. 336, № 15. P. 1059–1064.
35. Akker M. van den et al. Aplastic anemia associated with systemic lupus erythematosus in children – case report and review of the literature // Clin. Case Reports. Wiley-Blackwell, 2014. Vol. 2, № 6. P. 319.
36. Shimamura A. Aplastic anemia and clonal evolution: germ line and somatic genetics // Hematol. Am. Soc. Hematol. Educ. Progr. The American Society of Hematology, 2016. Vol. 2016, № 1. P. 74.